X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (390) 390
index medicus (260) 260
oncology (183) 183
cancer (169) 169
pharmacology & pharmacy (159) 159
pegylated liposomal doxorubicin (146) 146
liposomal daunorubicin (139) 139
chemotherapy (132) 132
female (126) 126
liposomes (116) 116
male (116) 116
animals (99) 99
doxorubicin (94) 94
drug delivery systems (93) 93
middle aged (91) 91
neoplasms - drug therapy (88) 88
liposomal doxorubicin (81) 81
adult (80) 80
nanoparticles (79) 79
antineoplastic agents - therapeutic use (78) 78
pegylated-liposomal doxorubicin (78) 78
drugs (74) 74
aged (71) 71
anthracyclines (70) 70
treatment outcome (64) 64
hematology (63) 63
nanotechnology (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (60) 60
antineoplastic agents - administration & dosage (58) 58
pharmacokinetics (58) 58
drug delivery (57) 57
toxicity (57) 57
drug-delivery (56) 56
doxorubicin - administration & dosage (54) 54
vehicles (52) 52
care and treatment (51) 51
breast-cancer (49) 49
nanoscience & nanotechnology (49) 49
chemistry, multidisciplinary (48) 48
drug therapy (48) 48
tumors (48) 48
health aspects (47) 47
metastatic breast-cancer (46) 46
solid tumors (46) 46
therapy (46) 46
antibiotics, antineoplastic - administration & dosage (45) 45
medicine & public health (45) 45
nanomedicine (45) 45
research (45) 45
daunorubicin (42) 42
daunorubicin - administration & dosage (42) 42
phase-ii (42) 42
phase-ii trial (42) 42
article (40) 40
kaposi's sarcoma (40) 40
phase-i (40) 40
leukemia (39) 39
analysis (38) 38
cardiotoxicity (38) 38
in-vivo (38) 38
doxorubicin - therapeutic use (37) 37
drug carriers (37) 37
trial (37) 37
in-vitro (34) 34
acute myeloid-leukemia (33) 33
antineoplastic agents - adverse effects (33) 33
sarcoma, kaposi - drug therapy (33) 33
vincristine (33) 33
active antiretroviral therapy (31) 31
antibiotics, antineoplastic - adverse effects (31) 31
pharmacology/toxicology (31) 31
acquired immunodeficiency syndrome - complications (30) 30
adolescent (30) 30
doxorubicin - adverse effects (30) 30
antibiotics, antineoplastic - therapeutic use (29) 29
antitumor-activity (29) 29
doxorubicin - analogs & derivatives (29) 29
doxorubicin - pharmacokinetics (29) 29
kaposis-sarcoma (29) 29
non-hodgkins-lymphoma (29) 29
prognosis (29) 29
risk factors (29) 29
acute myelogenous leukemia (28) 28
aids (28) 28
antineoplastic agents - pharmacokinetics (28) 28
biochemistry & molecular biology (28) 28
child (28) 28
clinical trials (28) 28
fractionated cyclophosphamide (28) 28
mice (28) 28
review (28) 28
antineoplastic agents - pharmacology (27) 27
cell line, tumor (27) 27
dose-response relationship, drug (27) 27
drug delivery systems - methods (27) 27
nanomedicine - methods (27) 27
cytarabine (26) 26
multidrug-resistance (26) 26
acute myeloid leukemia (25) 25
nanoparticles - chemistry (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best Practice & Research Clinical Haematology, ISSN 1521-6926, 06/2019, Volume 32, Issue 2, pp. 127 - 133
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 06/2018, Volume 11, pp. 3425 - 3434
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2014, Volume 93, Issue 12, pp. 2011 - 2018
Therapeutic options for patients with relapsed or refractory acute leukemia are still undefined and often unsatisfactory. We report the outcome of 79 patients... 
Relapsed-refractory acute leukemias | AML | ALL | Fludarabine | Cytarabine | Medicine & Public Health | Hematology | Stem cell transplant | Oncology | Liposomal daunorubicin | HSCT | DAUNOXOME | ACUTE LYMPHOCYTIC-LEUKEMIA | ADULTS | ACUTE MYELOID-LEUKEMIA | ACUTE LYMPHOBLASTIC-LEUKEMIA | 1ST RELAPSE | ENCAPSULATED DAUNORUBICIN | SALVAGE THERAPY | RISK ACUTE-LEUKEMIA | MULTIDRUG-RESISTANCE | HEMATOLOGY | Humans | Middle Aged | Drug Evaluation | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Diarrhea - chemically induced | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Retrospective Studies | Neutropenia - chemically induced | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - therapy | Drug Administration Schedule | Vidarabine - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Combined Modality Therapy | Vidarabine - analogs & derivatives | Granulocyte Colony-Stimulating Factor - therapeutic use | Remission Induction | Cytarabine - administration & dosage | Neutropenia - drug therapy | Daunorubicin - adverse effects | Blood Component Transfusion | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Vidarabine - administration & dosage | Liposomes | Relapse | Anthracyclines | Stem cells | Acute leukemia | Transplantation | Hematopoietic stem cells | Diseases | Index Medicus
Journal Article
RSC Advances, ISSN 2046-2069, 3/2014, Volume 4, Issue 27, pp. 1419 - 14114
This study reports the use of chitosan microcapsules for daunorubicin delivery via an oral route. The potential oral delivery of the daunorubicin/chitosan... 
BREAST-CANCER | VITRO | CELLS | THERAPY | DRUG DELIVERIES | PHARMACOKINETICS | IN-VIVO | BIOLOGICAL-ACTIVITY | NON-HODGKINS-LYMPHOMA | LIPOSOMAL DAUNORUBICIN | CHEMISTRY, MULTIDISCIPLINARY | Mice | Chitosan | Inhibition | Tumours | Vehicles
Journal Article
Iranian Journal of Basic Medical Sciences, ISSN 2008-3866, 12/2015, Volume 18, Issue 12, pp. 1199 - 1208
Objective(s): The objective of this study was to investigate the interaction of daunorubicin (DNR) and cardiac myosin (CM) and the changes in mice hearts to... 
Myocardial enzyme | Cardiac myosin | Daunorubicin | Cardiotoxicity | Fluorescence qusenching | MEDICINE, RESEARCH & EXPERIMENTAL | CALSEQUESTRIN | CARDIOMYOPATHY | COMBINATION | LIPOSOMAL DAUNORUBICIN | PROTECTS | HUMAN-SERUM-ALBUMIN | ANTHRACYCLINE | DRUGS | PHARMACOLOGY & PHARMACY | DISACCHARIDE | BINDING | Fluorescence quenching | Original
Journal Article
Drug Delivery System, ISSN 0913-5006, 2017, Volume 32, Issue 2, pp. 100 - 108
Journal Article
Journal Article
Expert Opinion on Orphan Drugs, ISSN 2167-8707, 04/2017, Volume 5, Issue 4, pp. 369 - 374
Introduction: Despite uninterrupted efforts made to develop newer drugs and schedules in the treatment of acute myeloid leukemia (AML), the induction of... 
liposomal daunorubicin | Acute myeloid leukemia | therapy | CPX-351 | AML | ADULTS | TANDEM DUPLICATION | MOLAR RATIO | I TREAT | OLDER PATIENTS | CYTARABINEDAUNORUBICIN | PHARMACOLOGY & PHARMACY | ANTICANCER DRUGS | PHASE-2 TRIAL
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2010, Volume 148, Issue 2, pp. 217 - 225
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2001, Volume 47, Issue 1, pp. 15 - 21
Journal Article